Evotec SE
EVO
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $660.7M
$1.86
▼ -2.11%
P/E
-2.87
Mkt Cap
$660.7M
52-Wk Range
$1.80–$4.27
52-Week Range
$1.80 - $4.27
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 46.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-33.8% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.17 vs -$0.05 consensus (-275.4% surprise). Revenue of $166.7M vs $174.1M expected (-4.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-275.4%
Revenue trend · last 8Q
—
—
—
—
-11%
+13%
-21%
-15%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$215.0M
$257.2M
$232.5M
$199.1M
$190.6M
$291.7M
$184.6M
$169.6M
Margins · last 8Q
Profit
-32.5%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jul 15, 2026
vs Industry
How EVO stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.